相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Yun Ling et al.
MOLECULAR CANCER (2022)
mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab
Vassiliki Rapti et al.
ONCOLOGY LETTERS (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12
Yan Liang et al.
CELL DEATH DISCOVERY (2021)
Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
Liyun Luo et al.
NATURE COMMUNICATIONS (2021)
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Chao Dong et al.
FRONTIERS IN PHARMACOLOGY (2021)
被撤回的出版物: Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation (Retracted article. See vol. 21, 2022)
Mingli Han et al.
MOLECULAR CANCER (2020)
Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer
Mingli Han et al.
CELL DEATH & DISEASE (2020)
Microscaled proteogenomic methods for precision oncology
Shankha Satpathy et al.
NATURE COMMUNICATIONS (2020)
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling
Zhanhong Chen et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
lncRNA ZNF649-AS1 Induces Trastuzumab Resistance by Promoting ATG5 Expression and Autophagy
Mingli Han et al.
MOLECULAR THERAPY (2020)
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Aranzazu Fernandez-Martinez et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer
J. Veeraraghavan et al.
ANNALS OF ONCOLOGY (2019)
Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
Tiia J. Honkanen et al.
SCIENTIFIC REPORTS (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)
Saranya Chumsri et al.
CLINICAL CANCER RESEARCH (2018)
被撤回的出版物: Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer (Retracted article. See vol. 61, 2022)
Huaying Dong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer
Alma D. Campos-Parra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
被撤回的出版物: Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation (Retracted article. See vol. 42, 2023)
Huaying Dong et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
被撤回的出版物: SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88 (Retracted article. See vol. 42, 2023)
Huaying Dong et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
Damien Cote et al.
PLOS ONE (2018)
Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
Agnieszka Adamczyk et al.
ONCOTARGETS AND THERAPY (2018)
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Yi Ding et al.
NATURE COMMUNICATIONS (2018)
Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab
Christos Christodoulou et al.
CANCER GENOMICS & PROTEOMICS (2018)
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F. Rimawi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Maki Tanioka et al.
CLINICAL CANCER RESEARCH (2018)
NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells
Liuting Yang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
Otilia Menyhart et al.
ONCOTARGET (2017)
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting
Agnieszka Adamczyk et al.
JOURNAL OF CANCER (2017)
Targeted therapies in breast cancer: New challenges to fight against resistance
Viviana Masoud et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab in the Treatment of Breast Cancer
Sofia Maximiano et al.
BIODRUGS (2016)
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
An Na Seo et al.
BRITISH JOURNAL OF CANCER (2016)
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
Alessandra Fabi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Meta-Analysis withR
James P. Howard et al.
Journal of Statistical Software (2016)
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
Helen Gogas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
L. Venturutti et al.
ONCOGENE (2016)
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
Sinead Toomey et al.
ONCOTARGET (2016)
Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer
Callie R. Merry et al.
ONCOTARGET (2016)
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Marta Hergueta-Redondo et al.
ONCOTARGET (2016)
HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
Albina Stocker et al.
PLOS ONE (2016)
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick et al.
BMC MEDICINE (2015)
Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer
Alice Chung et al.
CLINICAL BREAST CANCER (2015)
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Ian J. Majewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The role of the insulin-like growth factor-1 system in breast cancer
Panagiotis F. Christopoulos et al.
MOLECULAR CANCER (2015)
miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation
Tao Ma et al.
ONCOLOGY REPORTS (2015)
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
Begona Martin-Castillo et al.
ONCOTARGET (2015)
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
Amir Sonnenblick et al.
ONCOTARGET (2015)
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
Leticia De Mattos-Arruda et al.
ONCOTARGET (2015)
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Ingrid A. Mayer
CURRENT BREAST CANCER REPORTS (2015)
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
M. I. Koukourakis et al.
BRITISH JOURNAL OF CANCER (2014)
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
G. Peiro et al.
BRITISH JOURNAL OF CANCER (2014)
Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska et al.
CLINICAL CANCER RESEARCH (2014)
HLA-G polymorphism and breast cancer
G. B. Rolfsen et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2014)
The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web
A. Dittrich et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
Angelo Gamez-Pozo et al.
PLOS ONE (2014)
Multidrug-resistant breast cancer: current perspectives
Heather L. Martin et al.
BREAST CANCER-TARGETS AND THERAPY (2014)
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy
Mamoru Takada et al.
BMC CANCER (2013)
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
Allan Lipton et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Carsten Denkert et al.
BREAST CANCER RESEARCH (2013)
Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
Rohit Singh et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2013)
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A. Gallardo et al.
BRITISH JOURNAL OF CANCER (2012)
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Eun-Jung Jung et al.
CANCER (2012)
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Sarat Chandarlapaty et al.
CLINICAL CANCER RESEARCH (2012)
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
M. Bates et al.
ANNALS OF ONCOLOGY (2011)
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Leiping Wang et al.
BMC CANCER (2011)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Devika Gajria et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Chang Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy
Dana Faratian et al.
PLOS ONE (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma
F. Vegran et al.
BRITISH JOURNAL OF CANCER (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
Julien J. M. Boone et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Natalia V. Sergina et al.
TRENDS IN MOLECULAR MEDICINE (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS):: An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer
Danny L. Costantini et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
Lyndsay N. Harris et al.
CLINICAL CANCER RESEARCH (2007)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
E Tan-Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Fixed effects vs. random effects meta-analysis models: Implications for cumulative research knowledge
JE Hunter et al.
INTERNATIONAL JOURNAL OF SELECTION AND ASSESSMENT (2000)
分享论文
